Las Vegas-based JanOne Inc. has announced its mission to tackle the growing medical need for non-opioid and non-addictive therapies to alleviate pain and addiction. As a clinical-stage biopharmaceutical outfit, the company specialises in identifying, acquiring, licensing, developing, partnering and commercializing such therapies. Operating across two segments, Biotechnology and Recycling, JanOne's landmark product candidate is JAN101 – a patented and sustained release pharmaceutical composition of sodium nitrite. Targeting poor blood flow to the extremities, JAN101 is aimed at those with diabetes or peripheral artery disease to manage the condition's pain. The firm also offers turnkey solutions for appliance recycling and replacement services for power suppliers and other energy efficiency program sponsors. Established in 1976 as Appliance Recycling Centers of America, the firm formally changed its name to JanOne Inc. in 2019.
JanOne Inc.'s ticker is JAN
The company's shares trade on the ASX stock exchange
They are based in Ultimo, Australia
There are 51-200 employees working at JanOne Inc.
It is https://janone.com/
JanOne Inc. is in the Technology sector